The option has an exercise price equal to the closing price of Autonomix’s common stock as reported by the Nasdaq Capital Market on March 17, 2025. The options have a ten-year term and vest in four ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies ...

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104 ...

The approved inducement grant comes as Etsy targets a stickier app experience as part of a strategy to reverse an ongoing ...

The grant was offered as material inducement to Zamansky’s employment as Amwell’s chief product and technology officer. The RSUs become vested as follows, subject to Zamansky’s continued ...

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks ...

Such grant was made under The Honest Company, Inc. 2023 Inducement Plan, which was approved and adopted on March 14, 2023, by the Company’s Compensation Committee of the Board of Directors.

The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2025 ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib fo ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Inc. 2022 Inducement Plan (the “2022 Inducement Plan”). For all of the grant recipients, 50% of the restricted stock units shall vest on the first anniversary of the grant date, and the remaining 50% ...